As of 2026-10-05, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (36.37) USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.96 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -380.6%.
The range of the Relative Valuation is (35.79) - (40.44) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.5x - 19.2x | 17.6x |
| Forward P/E multiples | 14.3x - 18.6x | 15.8x |
| Fair Price | (35.79) - (40.44) | (36.37) |
| Upside | -376.2% - -412.1% | -380.6% |
| Date | P/E |
| 2026-10-02 | -5.96 |
| 2026-10-01 | -5.91 |
| 2026-09-30 | -6.06 |
| 2026-09-29 | -5.81 |
| 2026-09-28 | -5.80 |
| 2026-09-25 | -5.46 |
| 2026-09-24 | -5.52 |
| 2026-09-23 | -5.50 |
| 2026-09-22 | -5.71 |
| 2026-09-21 | -5.57 |
| 2026-09-18 | -5.61 |
| 2026-09-17 | -5.76 |
| 2026-09-16 | -5.84 |
| 2026-09-15 | -5.65 |
| 2026-09-14 | -6.03 |
| 2026-09-11 | -5.96 |
| 2026-09-10 | -5.84 |
| 2026-09-09 | -6.09 |
| 2026-09-08 | -6.21 |
| 2026-09-04 | -6.48 |
| 2026-09-03 | -6.45 |
| 2026-09-02 | -6.48 |
| 2026-09-01 | -6.21 |
| 2026-08-31 | -6.13 |
| 2026-08-28 | -6.25 |
| 2026-08-27 | -6.35 |
| 2026-08-26 | -6.51 |
| 2026-08-25 | -6.48 |
| 2026-08-24 | -6.48 |
| 2026-08-21 | -6.19 |
| 2026-08-20 | -6.04 |
| 2026-08-19 | -6.21 |
| 2026-08-18 | -6.12 |
| 2026-08-17 | -5.90 |
| 2026-08-14 | -6.05 |
| 2026-08-13 | -6.18 |
| 2026-08-12 | -6.21 |
| 2026-08-11 | -6.22 |
| 2026-08-10 | -6.35 |
| 2026-08-07 | -6.33 |
| 2026-08-06 | -6.14 |
| 2026-08-05 | -6.08 |
| 2026-08-04 | -6.13 |
| 2026-08-03 | -5.96 |
| 2026-07-31 | -5.79 |
| 2026-07-30 | -5.98 |
| 2026-07-29 | -5.73 |
| 2026-07-28 | -5.80 |
| 2026-07-27 | -5.85 |
| 2026-07-24 | -5.88 |